Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17964376 | 1.00 | KDM4E (0.36) | KDM4ETERTF2 | |
| SCHEMBL17964373 | 0.94 | KDM4E (0.32) | KDM4E | |
| SCHEMBL29540302 | 0.94 | KDM4E (0.32) | KDM4E | |
| SCHEMBL16574864 | 0.94 | KDM4E (0.40) | KDM4ETERTF2 | |
| SCHEMBL31683968 | 0.92 | KDM4E (0.34) | KDM4E | |
| SCHEMBL16289573 | 0.92 | KDM4E (0.34) | KDM4E | |
| SCHEMBL31683959 | 0.92 | KDM4E (0.34) | KDM4E | |
| SCHEMBL16288861 | 0.92 | KDM4E (0.34) | KDM4E | |
| SCHEMBL31684002 | 0.92 | TERT (0.31) | TERT | |
| SCHEMBL17964380 | 0.92 | TERT (0.31) | TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | KDM4E 4623/4885TERT 2851/4885F2 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.